Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Fargnoli, MC; Esposito, M; Ferrucci, S; Girolomoni, G; Offidani, A; Patrizi, A; Peris, K; Costanzo, A; Malara, G; Pellacani, G; Romanelli, M; Amerio, P; Cristaudo, A; Flori, ML; Motolese, A; Betto, P; Patruno, C; Pigatto, P; Sirna, R; Stinco, G; Zalaudek, I; Bianchi, L; Boccaletti, V; Cannavò, SP; Cusano, F; Lembo, S; Mozzillo, R; Gallo, R; Potenza, C; Rongioletti, F; Tiberio, R; Grieco, T; Micali, G; Persechino, S; Pettinato, M; Pucci, S; Savi, E; Stingeni, L; Romano, A; Argenziano, G, , Dupilumab, Italian, National, Access, Program, (Dup-INAP, group).
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
J Dermatolog Treat. 2021; 32(5):507-513
Doi: 10.1080/09546634.2019.1682503
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Zalaudek Iris
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. OBJECTIVE: To assess dupilumab effectiveness and safety in adults with moderate-to-severe AD in a real-life Italian multicentre retrospective cohort. METHODS: Adult moderate-to-severe AD patients, referring to 39 Italian centers, received dupilumab in the context of a national patient access program. Disease assessment was performed at baseline, after 4 and 16 weeks of treatment using Eczema-Area-and-Severity-Index (EASI) score, itch and sleep numerical-rating-score (itch-NRS, sleep-NRS) and Dermatology-Life-Quality-Index (DLQI). RESULTS: A total of 109 (71 M/38F) patients was studied. There was a significant reduction in EASI score, itch-NRS, sleep-NRS and DLQI from baseline to week 4 and a further significant decline to week 16. EASI 50, EASI75 and EASI90 were achieved by 59.6%, 28.4% and 9.3% of patients at 4 weeks and by 87.2%, 60.6% and 32.4% of them at 16 weeks, respectively. Adverse events were experienced by 19.2% (21/109) of the patients and they were all mild in intensity, being conjunctivitis the most common side effect. CONCLUSIONS: Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult - administration & dosage
- Aged - administration & dosage
- Aged, 80 and over - administration & dosage
- Antibodies, Monoclonal, Humanized - administration & dosage
- Cohort Studies - administration & dosage
- Dermatitis, Atopic - drug therapy
- Female - administration & dosage
- Humans - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Pruritus - drug therapy
- Quality of Life - administration & dosage
- Retrospective Studies - administration & dosage
- Severity of Illness Index - administration & dosage
- Sleep - administration & dosage
- Treatment Outcome - administration & dosage
- Young Adult - administration & dosage
- Find related publications in this database (Keywords)
- Atopic dermatitis
- dupilumab
- real-life